West Pharmaceutical Services, Inc.'s lumpy performance, declining profits & high valuation raise concerns. Click for why WST ...

West Pharmaceutical Services shares have dropped 35% in 2025, despite better-than-expected Q1 results, with forward guidance ...

Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q4 CY2024 results , with sales up 2.3% year on year to $748.8 million. On the other hand, the company’s full-year ...

Healthcare products company West Pharmaceutical Services (NYSE:WST) announced in Q1 CY2025, but sales were flat year on year at $698 million. The company’s full-year revenue guidance of $2.96 ...

This means West often remains the primary elastomer packaging provider for the entire time a drug remains on market, which may extend well beyond 10 years for many drugs. Pharmaceutical companies ...

Healthcare products company West Pharmaceutical Services (NYSE:WST) will be reporting results tomorrow before market open. Here’s what investors should know. West Pharmaceutical Services beat ...

This means West often remains the primary elastomer packaging provider for the entire time a drug remains on market, which may extend well beyond 10 years for many drugs. Pharmaceutical companies ...

West Pharmaceutical registered net sales of $746.9 million, down 0.1% year over year. The figure, however, beat the Zacks Consensus Estimate by 5.1%. The company recorded an organic net sales ...

West Pharmaceutical Services Inc . (NYSE: WST) Vice President and Treasurer Charles Witherspoon has recently sold company stock valued at over $300,000, according to a new SEC filing.The ...

Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 2.3% year on year to $748.8 million.